Related Experiment Video
Updated: Feb 12, 2026
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG,
Keiya Uriu1, Yu Kaku2, Yusuke Kosugi3
1Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Abstract:
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron variant has continuously diverged, and multiple of its sublineages are circulating worldwide. To reduce the coronavirus disease 2019 (COVID-19) with infection of the SARS-CoV-2 Omicron sublineages, some types of variant-matched vaccines have been developed and approved, such as Omicron JN.1-based vaccines and Omicron LP.8.1-based vaccines, in multiple countries, including Japan. Since, at the beginning of 2025, the Omicron XEC variant was predominant over other variants in Japan, two Japanese pharmaceutical companies have developed Omicron XEC-based vaccines. In this study, we evaluated the neutralizing antibody response induced by Omicron XEC-based vaccine and our data showed that both Omicron XEC-based vaccines can enhance the neutralizing titer of sera against a broad range of SARS-CoV-2 variants.
Related Concept Videos
01:36Humoral Immune Responses
01:51Vaccinations
02:30Histone Variants at the Centromere
01:38What is the Immune System?
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:13meta-Directing Deactivators: –NO2, –CN, –CHO, –CO2R, –COR, –CO2H